COMMUNIQUÉS West-GlobeNewswire

Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
23/09/2025
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces [...]
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
23/09/2025
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as [...]
SEED Therapeutics Completes $30 Million Series A-3 Financing
23/09/2025
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers [...]
Tilray Beverages Unveils New Fall Seasonal Craft Brews with Oktoberfest-Inspired Lineup
23/09/2025
ATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is raising a stein to the season with a festive lineup of [...]
BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer
23/09/2025
Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to commercialization BOSTON, Sept. 23 [...]
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
23/09/2025
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
23/09/2025
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively. Scilex (together with its affiliates) owns [...]
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
23/09/2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc. , an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, [...]
Labviva Kicks Off Smart Lab of the Future Tour
23/09/2025
Life sciences procurement leader showcases AI-driven supply chain innovation at global events BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Labviva , the leading AI-powered procurement platform for life sciences, today [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 BST. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Addex Appoints Bank of New York Mellon as Depositary Bank
23/09/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23/09/2025
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expression Myotonic [...]
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1
23/09/2025
La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1 Admission obtenue pour la thérapie génique AAV unique [...]
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rollout Demand for AGAMREE [...]
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
23/09/2025
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
AMN Healthcare Announces Pricing of Senior Notes Offering
22/09/2025
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of $400.0 [...]
Fortrea Appoints William Sharbaugh to Board of Directors
22/09/2025
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company’s Board [...]
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
22/09/2025
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Pages